Subcutaneous beloranib: Phase III started

Zafgen began the double-blind, placebo-controlled, U.S. Phase III bestPWS trial to evaluate 1.8 and 2.4 mg subcutaneous beloranib twice weekly for 6 months in 84 patients ages >=12 years. The trial in...